Inactive Instrument

Ergomed

Equities

ERGO

GB00BN7ZCY67

Biotechnology & Medical Research

Ergomed : award of share options to Directors and Company Secretary

July 03, 2018 at 03:54 am EDT

Enquiries:

Ergomed plc Tel: +44 (0) 1483 503 205

Stephen Stamp (Chief Executive Officer)

Numis Securities Limited Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

N+1 Singer Tel: +44 (0) 20 7496 3000

Aubrey Powell (Joint Broker)

Consilium Strategic Communications - for UK enquiries Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Olivia Manser ergomed@consilium-comms.com

MC Services - for Continental European enquiries Tel: +49 211 5292 5222

Anne Hennecke

Attachments

Original document
Permalink

Disclaimer

Ergomed plc published this content on 03 July 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 03 July 2018 07:53:03 UTC

Latest news about Ergomed

Ergomed Delists From London Stock Exchange	Nov. 14	MT
Permira Advisers Ltd. completed the acquisition of Ergomed plc from Amati Global Investors Ltd. and others.	Nov. 12	CI
Milton plans energy focus; Guild completes fund raise	Nov. 09	AN
UK Court Clears Permira's Ergomed Purchase	Nov. 09	MT
Ergomed says conditions satisfied for Permira takeover	23-10-27	AN
Permira's Takeover of Ergomed Nears Completion	23-10-27	MT
Ergomed's Takeover by Permira Advisers Expected to Take Effect mid-November	23-10-23	MT
Ergomed Shareholders Back Eden AcquisitionCo's Bid	23-10-13	MT
Ergomed plc acquired Panacea Pharma Projects Limited from Stuart Colligon.	23-10-09	CI
The FTSE 100 Closed Up as UK Retail Sales, Consumer Confidence Data Offers Economic Hope	23-09-22	DJ
Ergomed first-half profit firms ahead of agreed takeover by Permira	23-09-22	AN
Ergomed Posts Flat H1 Profit; Revenue Rises	23-09-22	MT
Earnings Flash (ERGO.L) ERGOMED Posts H1 Revenue GBP76.7M	23-09-22	MT
Ergomed plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-22	CI
FTSE 100 Closes Modestly Lower on Asia Caution	23-09-04	DJ
Stocks wilt after early promise with US closed	23-09-04	AN
British Land Shares Lack Drivers as City Valuations Dip	23-09-04	DJ
ANALYST RECOMMENDATIONS : Ergomed, Dollar general, Salesforce, Citigroup, Goldman Sachs...	23-09-04
AIM WINNERS & LOSERS: Physiomics brings in COO; Ergomed receives bid	23-09-04	AN
Ergomed agrees GBP700 million takeover by Permira	23-09-04	AN
Stocks lifted by hopes for US rate pause	23-09-04	AN
Ergomed Agrees GBP703 Million Takeover by Permira Funds	23-09-04	MT
CMC names new CFO; takeover offer for Ergomed	23-09-04	AN
Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc for approximately £700 million.	23-09-03	CI
FTSE 100 Closes Tuesday Up 0.2% Lifted by Unilever, Miners	23-07-25	DJ

Chart Ergomed

Duration

Period

More charts

Company Profile

Ergomed PLC is a United Kingdom-based company that is primarily focused on providing specialized services to the biopharmaceutical industry. The Company operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The Company serves over 100 countries. It operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Companies subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-09-23 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.11%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-9.05%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs